129 related articles for article (PubMed ID: 25035248)
1. Epirubicin combined with oxaliplatin and 5-day continuous infusion of 5-fluorouracil as a first-line treatment for metastatic gastric cancer: treatment outcomes and analysis of prognostic factors.
Zhu X; Zhao X; Peng W; Sun S; Cao J; Ji D; Liu X; Wang C; Huang M; Yu H; Guo W; Li J; Yin J
J Cancer Res Clin Oncol; 2015 Jan; 141(1):109-18. PubMed ID: 25035248
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical trial of advanced and metastatic gastric cancer based on continuous infusion of 5-fluorouracil combined with epirubicin and oxaliplatin.
Zhu X; Leaw J; Gu W; Qian Y; Du H; Wang B; Hong X; Yin J
J Cancer Res Clin Oncol; 2008 Sep; 134(9):929-36. PubMed ID: 18343948
[TBL] [Abstract][Full Text] [Related]
3. Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen.
Liu R; Huang M; Zhao X; Peng W; Sun S; Cao J; Ji D; Wang C; Guo W; Li J; Yin J; Zhu X
Oncotarget; 2015 Nov; 6(36):39018-27. PubMed ID: 26528696
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients.
Sun S; Wang LP; Zhang J; Yang XY; Zhang QL; Jia Z; Hu XC; Wang BY
Med Oncol; 2012 Jun; 29(2):418-24. PubMed ID: 21298496
[TBL] [Abstract][Full Text] [Related]
5. Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
Ocvirk J; Reberšek M; Skof E; Hlebanja Z; Boc M
Am J Clin Oncol; 2012 Jun; 35(3):237-41. PubMed ID: 21399488
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2.
Turkeli M; Aldemir MN; Cayir K; Simsek M; Bilici M; Tekin SB; Yildirim N; Bilen N; Makas I
Asian Pac J Cancer Prev; 2015; 16(3):985-9. PubMed ID: 25735393
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study.
Neri B; Pantaleo P; Giommoni E; Grifoni R; Paoletti C; Rotella V; Pantalone D; Taddei A; Mercatelli A; Tonelli P
Br J Cancer; 2007 Apr; 96(7):1043-6. PubMed ID: 17353926
[TBL] [Abstract][Full Text] [Related]
8. Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer.
Petrioli R; Marrelli D; Roviello F; D'Ignazio A; Torre P; Chirra M; Savelli V; Ambrosio MR; Francini G; Calomino N; Farsi M; Vernillo R; Francini E
Surg Oncol; 2020 Mar; 32():2-7. PubMed ID: 31670056
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer.
Zhang CX; Huang S; Xu N; Fang JW; Shen P; Bao YH; Mou BH; Shi MG; Zhong XL; Xiong PJ
Anticancer Drugs; 2007 Jun; 18(5):581-6. PubMed ID: 17414627
[TBL] [Abstract][Full Text] [Related]
10. [Preliminary study of biweekly regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer].
Wang ZH; Guo J; Chen Z; Li CZ; Sheng LJ; Zhou DG; Liu B; Liu J; Wang QC; Zhang EN
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):389-91. PubMed ID: 18953843
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of epirubicin plus oxaliplatin and fluorouracil as first-line chemotherapy for advanced gastric cancer.
Zhao JG; Xiong JP; Xiang XJ; Qiu F; Zhang L; Yu F
Ai Zheng; 2009 Jan; 28(1):42-4. PubMed ID: 19448415
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer.
Zhang ZD; Kong Y; Yang W; Zhang B; Zhang YL; Ma EM; Liu HX; Chen XB; Hua YW
World J Surg Oncol; 2014 Apr; 12():115. PubMed ID: 24758484
[TBL] [Abstract][Full Text] [Related]
13. 5-Fluorouracil, epirubicin and cisplatin in the treatment of metastatic gastric carcinoma: a retrospective analysis of 68 patients.
Ozkan K; Turkkan E; Ender K; Mutlu D; Murat A; Nalan B; Abdulmecit Y; Osman M
Indian J Cancer; 2005; 42(2):85-8. PubMed ID: 16141507
[TBL] [Abstract][Full Text] [Related]
14. [FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer].
Yan D; Dai H
Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):217-9. PubMed ID: 19615264
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer.
Schønnemann KR; Jensen HA; Yilmaz M; Jensen BY; Larsen O; Pfeiffer P
Br J Cancer; 2008 Sep; 99(6):858-61. PubMed ID: 19238627
[TBL] [Abstract][Full Text] [Related]
16. FOLFOX (oxaliplatin and 5 fluorouracil/leucovorin) in patients with untreated metastatic gastric adenocarcinoma Phase II study.
Mohammad HA; Magdy FM; Mahmoud OM
Indian J Cancer; 2011; 48(4):460-5. PubMed ID: 22293261
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of the efficacy and safety of oxaliplatin plus 5-fluorouracil/leucovorin (modified FOLFOX6) with advanced gastric cancer patients having a good or poor performance status.
Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Esenkaya A; Uzunoglu S; Cicin I
Asian Pac J Cancer Prev; 2015; 16(6):2355-9. PubMed ID: 25824764
[TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial.
Anter AH; Abdel-Latif RM
Med Oncol; 2013 Mar; 30(1):451. PubMed ID: 23307258
[TBL] [Abstract][Full Text] [Related]
19. Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort.
Pernot S; Mitry E; Samalin E; Dahan L; Dalban C; Ychou M; Seitz JF; Turki H; Mazard T; Zaanan A; Lepère C; Vaillant JN; Landi B; Rougier P; Taieb J
Gastric Cancer; 2014 Apr; 17(2):341-7. PubMed ID: 23739764
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer.
Moehler M; Mahlberg R; Heinemann V; Obermannová R; Kubala E; Melichar B; Weinmann A; Scigalla P; Tesařová M; Janda P; Hédouin-Biville F; Mansoor W
Gastric Cancer; 2017 Mar; 20(2):358-367. PubMed ID: 27255289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]